Aclarion's Nociscan Platform Revolutionizes Chronic Low Back Pain Diagnosis and Treatment

Aclarion, Inc. (NASDAQ: ACON) is emerging as a key player in the healthcare technology sector with its groundbreaking Nociscan platform, aimed at revolutionizing the diagnosis and management of chronic low back pain (cLBP). This condition affects approximately 266 million people worldwide and incurs substantial healthcare costs, with U.S. expenditures alone reaching up to $134.5 billion annually.

The Nociscan platform stands out as the first evidence-supported software-as-a-service (SaaS) solution that utilizes Magnetic Resonance spectroscopy (MRS), proprietary signal processing techniques, and augmented intelligence algorithms. It noninvasively differentiates between painful and nonpainful discs in the lumbar spine, providing crucial insights to healthcare providers for improved diagnostic precision and treatment planning.

Aclarion has recently achieved a significant milestone with the completion of the first Nociscan exams in the LIFEHAB trial. This randomized control trial, conducted in Norway, compares lumbar interbody fusion surgery with multidisciplinary rehabilitation for chronic low back pain. The trial, involving 202 patients, utilizes Nociscan's advanced diagnostic technology to assess how MRS biomarkers correlate with treatment responses.

Brett Ness, Aclarion's CEO, emphasized the importance of this development, stating, "We are excited to see the LIFEHAB Trial progressing on schedule and look forward to the results of the study and to the role we expect Nociscan data to play in not only helping physicians determine which discs to treat but in potentially helping to predict which treatment option is optimal for a particular patient."

Aclarion has also expanded its presence in the U.S. market, announcing a key commercial agreement with Sheridan Community Hospital in Michigan. This partnership marks the company's entry into central Michigan and involves collaboration with Dr. John Keller, a leading neurosurgeon. The agreement aims to further validate Nociscan's clinical effectiveness and demonstrates the platform's potential to advance noninvasive, cost-effective diagnostics for disc pain.

In addition to its commercial agreements, Aclarion has launched two major clinical trials to substantiate Nociscan's benefits. The Clinical Utility and Economic (CLUE) Trial aims to assess how Nociscan's AI-generated biomarker data impacts surgical treatment decisions. The CLARITY trial, a gold-standard, multicenter, prospective randomized study, will provide definitive evidence on the advantages of incorporating Nociscan data into surgical decision-making processes.

Aclarion's innovative approach has recently garnered industry recognition with its addition to the PRISM Emerging Medical Devices Index. This inclusion highlights Aclarion's position as a leading innovator in the medtech sector and can increase its market visibility, credibility, and attractiveness to investors. As the U.S. medical devices market is projected to grow to nearly $315 billion by 2032, Aclarion's Nociscan is well-positioned to capture a portion of the $40 billion lumbar spine diagnostics and treatment market.

The company's efforts to address chronic low back pain through innovative, noninvasive technology underscore its potential to make a significant impact in the healthcare sector. With its expanding clinical partnerships, ongoing trials, and recent industry recognition, Aclarion is positioning itself strongly within the healthcare technology market, potentially transforming the approach to chronic low back pain management and improving patient outcomes worldwide.